Hypercoagulopathy in Severe COVID-19: Implications for Acute Care: Implications for Acute Care

Alicia A.C. Waite; Olly Hamilton; Roberto Pizzi; Walter Ageno; Ingeborg D. Welters

doi:10.1055/s-0040-1721487

Hypercoagulopathy in Severe COVID-19: Implications for Acute Care: Implications for Acute Care

Alicia A.C. Waite
, Olly Hamilton
, Roberto Pizzi
, Walter Ageno
, Ingeborg D. Welters

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

COVID-19 was first described in late 2019 and has since developed into a pandemic affecting more than 21 million people worldwide. Of particular relevance for acute care is the occurrence of COVID-19-associated coagulopathy (CAC), which is characterised by hypercoagulability, immunothrombosis and venous thromboembolism, and contributes to hypoxia in a significant proportion of patients. This review describes diagnosis and treatment of CAC in the emergency department and in intensive care. We summarise the pathological mechanisms and common complications of CAC such as pulmonary thrombosis and venous thromboembolic events and discuss current strategies for thromboprophylaxis and therapeutic anti-coagulation in the acute care setting.

Original language	English
Pages (from-to)	1654-1667
Number of pages	14
Journal	Thrombosis and Haemostasis
Volume	120
Issue number	12
DOIs	https://doi.org/10.1055/s-0040-1721487
Publication status	Published - 1 Dec 2020
Externally published	Yes

Keywords

anti-coagulation
coagulopathy
immunothrombosis
severe acute respiratory syndrome
venous thrombosis

Access to Document

10.1055/s-0040-1721487

Cite this

@article{0978e54549454990bd6caa155c672d8c,

title = "Hypercoagulopathy in Severe COVID-19: Implications for Acute Care: Implications for Acute Care",

abstract = "COVID-19 was first described in late 2019 and has since developed into a pandemic affecting more than 21 million people worldwide. Of particular relevance for acute care is the occurrence of COVID-19-associated coagulopathy (CAC), which is characterised by hypercoagulability, immunothrombosis and venous thromboembolism, and contributes to hypoxia in a significant proportion of patients. This review describes diagnosis and treatment of CAC in the emergency department and in intensive care. We summarise the pathological mechanisms and common complications of CAC such as pulmonary thrombosis and venous thromboembolic events and discuss current strategies for thromboprophylaxis and therapeutic anti-coagulation in the acute care setting.",

keywords = "anti-coagulation, coagulopathy, immunothrombosis, severe acute respiratory syndrome, venous thrombosis",

author = "Waite, \{Alicia A.C.\} and Olly Hamilton and Roberto Pizzi and Walter Ageno and Welters, \{Ingeborg D.\}",

year = "2020",

month = dec,

day = "1",

doi = "10.1055/s-0040-1721487",

language = "English",

volume = "120",

pages = "1654--1667",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Georg Thieme Verlag",

number = "12",

}

TY - JOUR

T1 - Hypercoagulopathy in Severe COVID-19: Implications for Acute Care: Implications for Acute Care

AU - Waite, Alicia A.C.

AU - Hamilton, Olly

AU - Pizzi, Roberto

AU - Ageno, Walter

AU - Welters, Ingeborg D.

PY - 2020/12/1

Y1 - 2020/12/1

N2 - COVID-19 was first described in late 2019 and has since developed into a pandemic affecting more than 21 million people worldwide. Of particular relevance for acute care is the occurrence of COVID-19-associated coagulopathy (CAC), which is characterised by hypercoagulability, immunothrombosis and venous thromboembolism, and contributes to hypoxia in a significant proportion of patients. This review describes diagnosis and treatment of CAC in the emergency department and in intensive care. We summarise the pathological mechanisms and common complications of CAC such as pulmonary thrombosis and venous thromboembolic events and discuss current strategies for thromboprophylaxis and therapeutic anti-coagulation in the acute care setting.

AB - COVID-19 was first described in late 2019 and has since developed into a pandemic affecting more than 21 million people worldwide. Of particular relevance for acute care is the occurrence of COVID-19-associated coagulopathy (CAC), which is characterised by hypercoagulability, immunothrombosis and venous thromboembolism, and contributes to hypoxia in a significant proportion of patients. This review describes diagnosis and treatment of CAC in the emergency department and in intensive care. We summarise the pathological mechanisms and common complications of CAC such as pulmonary thrombosis and venous thromboembolic events and discuss current strategies for thromboprophylaxis and therapeutic anti-coagulation in the acute care setting.

KW - anti-coagulation

KW - coagulopathy

KW - immunothrombosis

KW - severe acute respiratory syndrome

KW - venous thrombosis

U2 - 10.1055/s-0040-1721487

DO - 10.1055/s-0040-1721487

M3 - Article

SN - 0340-6245

VL - 120

SP - 1654

EP - 1667

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 12

ER -

Hypercoagulopathy in Severe COVID-19: Implications for Acute Care: Implications for Acute Care

Abstract

Keywords

Access to Document

Fingerprint

Cite this